NKMax America Revenue and Competitors
Estimated Revenue & Valuation
- NKMax America's estimated annual revenue is currently $17.1M per year.
- NKMax America's estimated revenue per employee is $155,000
- NKMax America's total funding is $11M.
Employee Data
- NKMax America has 110 Employees.
- NKMax America grew their employee count by -5% last year.
NKMax America's People
Name | Title | Email/Phone |
---|---|---|
1 | CTO | Reveal Email/Phone |
2 | VP Marketing | Reveal Email/Phone |
3 | Director, Regulatory Affairs | Reveal Email/Phone |
NKMax America Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is NKMax America?
NKMax America is harnessing the power of the body's immune system through the development of unique Natural Killer (NK) cell therapies. NK cell adoptive immunotherapy enhances a patient's ability to destroy abnormal cells. The mission of NKMax is to improve patients' lives in a safe and natural way through innovative cell therapy products and to ultimately become the global leader in immune cell therapeutics. More information can be found on our website www.nkmaxamerica.com
keywords:N/A$11M
Total Funding
110
Number of Employees
$17.1M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.5M | 112 | 19% | N/A |
#2 | $7.5M | 112 | 15% | N/A |
#3 | $28M | 112 | 51% | N/A |
#4 | $30.5M | 113 | 15% | N/A |
#5 | $26M | 114 | 9% | N/A |